-
#ASCO24: A roundup of the latest data from Merus, MorphoSys and others
24 May 2024 15:37 GMT
Read on for news about Immunocore, Arcus, CG Oncology, Genmab, Merck and GSK:
Merus stock spikes on data in head and neck squamous cell carcinoma: The biotech’s shares $MRUS rose more than 20% on Friday morning after sharing a Phase 2 …
-
Erasca restructures; Novartis moves to complete MorphoSys deal
17 May 2024 15:32 GMT
… on Bristol Myers Squibb, MorphoSys and Galapagos that you … billion deal to acquire Morphosys after meeting the conditions … acceptance from 79.6% of Morphosys’ total share capital, surpassing … on new safety concerns for Morphosys’ cancer drug pelabresib. — Ned …
-
Novartis to acquire nearly 12 percent stake of MorphoSys AG
16 May 2024 13:28 GMT
… for the shares of MorphoSys.
According to the company … total share capital of MorphoSys, including purchases by Novartis … have not tendered their MorphoSys shares, including shares represented … progress the integration of MorphoSys, including full access to …
-
Novartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash Deal
16 May 2024 11:21 GMT
… tender offer conditions to acquire MorphoSys AG (MOR) for EUR 68 … 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance …
-
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
16 May 2024 09:40 GMT
… shares of MorphoSys AG (“MorphoSys”), including all shares represented by MorphoSys American … , the “Recommendation Statements”). THE MORPHOSYS SHAREHOLDERS AND OTHER INVESTORS ARE … Solicitation/Recommendation Statement, MorphoSys and the Bidder will file …
-
STAT+: Novartis’ $3 billion MorphoSys boondoggle
02 May 2024 13:34 GMT
… : [email protected].
Novartis’ $3 billion MorphoSys boondoggle
Oh man, there I …
-
MorphoSys AG Reports First Quarter 2024 Financial Results
29 Apr 2024 20:19 GMT
… the pending acquisition of MorphoSys by Novartis, MorphoSys will not be hosting … contact information provided below.
About MorphoSys
At MorphoSys, we are driven by … CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to …
-
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
29 Apr 2024 17:37 GMT
… bone marrow.
Physicians participating in MorphoSys’ Phase 3 study have observed … ample resources currently unavailable to MorphoSys as a standalone biotech company … the situation.
Despite this setback, MorphoSys affirmed its acquisition by Novartis …
-
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Bu...
29 Apr 2024 15:53 GMT
… group, STAT reported. MorphoSys has already informed the … agreement between Novartis and MorphoSys in February 2024. Earlier … acquisition.
In November 2023, MorphoSys posted mixed Phase III … an application for pelabresib.
MorphoSys is scheduled to present …
-
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
29 Apr 2024 15:37 GMT
… course, do keep in touch….
MorphoSys is dealing with an emerging … has learned. Physicians involved with MorphoSys’ completed Phase 3 study have …